Monthly Archives: January 2014

Biotech China to Showcase Industrial Parks

January 27, 2014 | Comments are closed

Biotech China will be an excellent opportunity to meet the key players in the Chinese and international bio industrial park and incubator scene. Bio Alps from Switzerland and clusters from other countries will also be present and participate in the first China Summit Forum on Bio-Medicine Industrial Park Development on...

D-Pharm Phase 2 Pancreatitis

January 19, 2014 | Comments are closed

D-Pharm Ltd (TASE:DPRM) has started a Phase 2 clinical trial of DP-b99 in patients with acute high-risk inflammation of the pancreas (pancreatitis). DP-b99 is a cell protective drug that addresses multiple mechanisms damaging to insulted cells. This double-blind, placebo-controlled, multicenter study is examining for the first time DP-b99’s efficacy in...

Can-Fite Phase III Fails

January 1, 2014 | Comments are closed

Can-Fite BioPharma (TASE:CFBI), (NYSE MKT:CANF) subsidiary OphthaliX Inc. (OTCBB:OPLI) released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist. The patients were randomized to receive two oral doses of...